|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 3/01/19 NovaBay Pharmaceuticals, Inc. 8-K:1,2,7,9 2/27/19 3:161K RDG Filings/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 14K 2: EX-10.1 Material Contract HTML 41K 3: EX-10.2 Material Contract HTML 57K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of earliest event reported: February 27, 2019
NovaBay Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
68-0454536 |
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
2000 Powell Street, Suite 1150, Emeryville, CA 94608
(Address of Principal Executive Offices) (Zip Code)
(510) 899-8800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
On February 27, 2019, NovaBay Pharmaceuticals, Inc. (the “Company”) entered into certain agreements pursuant to a loan (the “Loan”) facilitated by China Kington Asset Management Co. Ltd. (“China Kington”). In connection with the Loan, the Company issued a promissory note (the “Note”) payable to Pioneer Pharma (Hong Kong) Company Limited (“Pioneer”), loaning the Company $1,000,000. The Note was issued on February 27, 2019.
The proceeds from the Note are to be used for general corporate purposes. The Loan includes an interest payment of $150,000 (the “Interest Payment”). The entire principal sum and the Interest Payment are payable in full upon the Company’s next financing with Pioneer, but in no event shall the term of the Loan extend beyond July 27, 2019. The Note may be prepaid in whole or in part without premium or penalty upon certain events occurring.
To secure the Note, China Kington shall have a perfected security interest in all tangible and intangible assets of the Company, pursuant to a security agreement (the “Security Agreement”) between the Company and China Kington, which was entered into on February 27, 2019.
The foregoing descriptions are qualified in their entirety by reference to the Note payable to the order of Pioneer and the Security Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
(a) The information set forth in Item 1.01 of the Current Report of Form 8-K is incorporated by reference into this Item 2.03.
Item 7.01. Regulation FD
The Company’s operating cash flow is not sufficient to support its ongoing operations. The above-described Loan will cover the Company’s operating expenses for approximately 30 days. During this time, the Company will evaluate its strategic options.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
|
10.1 |
Promissory Note Payable to Pioneer Pharma (Hong Kong) Company Limited, dated February 27, 2019 |
|
|
10.2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NovaBay Pharmaceuticals, Inc. |
|||
|
By: |
/s/ Justin Hall |
||
|
Senior Vice President, General Counsel |
|||
Dated: March 1, 2019
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 7/27/19 | None on these Dates | |||
| Filed on: | 3/1/19 | |||
| For Period End: | 2/27/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/04/22 NovaBay Pharmaceuticals, Inc. S-1 5:953K RDG Filings/FA 12/01/21 NovaBay Pharmaceuticals, Inc. S-1 15:1.1M RDG Filings/FA 3/25/21 NovaBay Pharmaceuticals, Inc. 10-K 12/31/20 101:10M RDG Filings/FA 11/12/20 NovaBay Pharmaceuticals, Inc. 10-Q 9/30/20 89:10M RDG Filings/FA 8/06/20 NovaBay Pharmaceuticals, Inc. 10-Q 6/30/20 93:10M RDG Filings/FA |